Hypothesis

We propose that combined pharmacological inhibition of NLRP3 inflammasome activity and selective blockade of IL-6 trans‑signaling will synergistically reverse age‑associated immunosenescence by restoring thymic epithelial function and preventing senescence‑associated secretory phenotype (SASP) expansion in perivascular adipose tissue (PVAT). The synergy arises because NLRP3‑driven IL-1β amplifies IL-6 trans‑signaling in PVAT macrophages, which in turn feeds back to the thymus via circulating gp130‑dependent signals that suppress IL‑7 production; simultaneous interruption of both loops breaks this feed‑forward circuit and permits SIRT2‑mediated deacetylation of NLRP3 to act as a reversible "off switch" in both compartments.

Mechanistic Rationale

• NLRP3 activation in thymic myeloid cells triggers IL‑1β release, damaging cortical thymic epithelial cells (cTECs) and lowering IL‑7/SCF expression【https://doi.org/10.1016/j.cmet.2013.09.010】.
• IL‑1β also stimulates NF‑κB in PVAT adipocytes and macrophages, increasing IL‑6 secretion that favors trans‑signaling (IL‑6/sIL‑6R/gp130) over classic signaling【https://pmc.ncbi.nlm.nih.gov/articles/PMC3883512/】.
• IL‑6 trans‑signaling promotes STAT3 activation in thymic stromal cells, further suppressing IL‑7 transcription and encouraging senescence of naïve T‑cell precursors【https://pubmed.ncbi.nlm.nih.gov/38643484/】.
• SIRT2 deacetylates NLRP3, reducing its inflammasome activity; pharmacological SIRT2 activators or NAD⁺ boosters have shown reversibility of chronic inflammation effects【https://www.drugtargetreview.com/news/55776/nlrp3-inflammasome-off-switch-reverses-effects-of-chronic-inflammation/】.
• Blocking IL‑6 trans‑signaling with an anti‑sgp130Fc antibody or small‑molecule inhibitor prevents STAT3‑driven SASP amplification without affecting classic IL‑6 anti‑apoptotic pathways, preserving metabolic homeostasis.

Testable Predictions

1. In aged mice, combined NLRP3 inhibitor (e.g., MCC950) and sgp130Fc treatment will increase cortical thymic cellularity and naïve CD4⁺/CD8⁺ T‑cell frequencies more than either monotherapy.
2. The combination will reduce IL‑1β and IL‑6 levels in thymic interstitial fluid and PVAT supernatant, correlating with restored IL‑7 and SCF mRNA in cTECs.
3. SIRT2 activity (measured by deacetylated NLRP3) will be elevated only in the combination group, indicating that IL‑6 trans‑signaling blockade permits SIRT2 access to NLRP3.
4. Adoptive transfer of T cells from combination‑treated aged hosts into young lymphopenic recipients will yield superior proliferative capacity and diverse TCR repertoire versus transfers from monotherapy or control groups.
5. In aged human peripheral blood mononuclear cells ex vivo, pretreatment with an NLRP3 inhibitor plus sgp130Fc will decrease senescence‑associated β‑galactosidase positivity and increase Ki‑67⁺ naïve T cells after anti‑CD3/CD28 stimulation.

Falsifiability

If the combination fails to outperform monotherapies in any of the above readouts—specifically, if thymic cellularity, naïve T‑cell frequencies, or IL‑7 expression do not show a statistically significant additive effect—then the hypothesis that NLRP3‑IL‑6 trans‑signaling synergy drives immunosenescence is falsified. Likewise, absence of increased SIRT2‑mediated NLRP3 deacetylation would argue against the proposed reversibility mechanism.

Translational Implication

Given that brain‑penetrant NLRP3 inhibitors such as NT‑0796 are already in clinical testing【https://www.nodthera.com/news/nodtheras-oral-nlrp3-inhibitor-nt-0796-enhances-and-sustains-weight-loss-in-combination-with-glp-1/】and sgp130Fc analogs are under investigation for inflammatory diseases, a combined regimen could be rapidly moved into phase II trials targeting immunosenescence biomarkers (e.g., naïve T‑cell ratio, thymic ultrasound echo‑brightness, circulating SASP factors).